A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

January 12, 2026

Study Completion Date

January 12, 2026

Conditions
Compensated Liver CirrhosisMetabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions
DRUG

BI 770371

BI 770371

DRUG

Placebo for BI 770371

Placebo for BI 770371

Trial Locations (13)

32127

Progressive Medical Research, Port Orange

33122

Evolution Clinical Trials, Miami

75203

The Liver Institute at Methodist Dallas, Dallas

77079

Houston Research Institute, Houston

78215

American Research Corporation at the Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research, San Antonio

80907

Peak Gastroenterology Associates-Colorado Springs-67762, Colorado Springs

85225

The Institute for Liver Health II dba Arizona Clinical Trials, Chandler

91763

Catalina Research Institute, LLC-Montclair-49051, Montclair

92118

Southern California Research Center, Coronado

92377

Inland Empire Clinical Trials, LLC, Rialto

92868

Knowledge Research Center, Orange

33174-3245

Blessed Health Care, Miami

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY